ClinicalTrials.govrestricted
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Pha
ClinicalTrials.gov study NCT07311577. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4